Tiragolumab Matching Placebo

DRUG4 trials

Sponsors

Hoffmann-La Roche

Conditions

Esophageal CancerEsophageal Squamous Cell CarcinomaNon-small Cell Lung Cancer (NSCLC)Small Cell Lung Carcinoma

Phase 2

A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer

CompletedNCT04619797

Hoffmann-La RocheNon-small Cell Lung Cancer (NSCLC)

Start: 2020-12-15End: 2025-11-20Updated: 2026-06-03

Phase 3

A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma

CompletedNCT04540211

Hoffmann-La RocheEsophageal Cancer

Start: 2020-10-30End: 2025-08-28Updated: 2026-08-27

A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy

CompletedNCT04543617

Hoffmann-La RocheEsophageal Squamous Cell Carcinoma

Start: 2020-09-28End: 2026-07-22Updated: 2026-09-14

Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

CompletedNCT04665856

Hoffmann-La RocheSmall Cell Lung Carcinoma

Start: 2020-12-21End: 2025-11-17Updated: 2026-09-18

Related Papers

Atezolizumab with or without tiragolumab in unresectable esophageal squamous cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III study.

2026-08-21

Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer: The Phase 3 SKYSCRAPER-06 Randomized Clinical Trial.

PubMed2026-04-30

First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial.

2026-01-01

Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial.

2026-01-01

Atezolizumab following definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma – a multicenter phase 2 trial (EPOC1802)

Nature Cancer2025-02-195 citations

Phase I pharmacokinetic, safety, and preliminary efficacy study of tiragolumab in combination with atezolizumab in Chinese patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology2024-03-073 citations

SKYSCRAPER-08: A phase III, randomized, double-blind, placebo-controlled study of first-line (1L) tiragolumab (tira) + atezolizumab (atezo) and chemotherapy (CT) in patients (pts) with esophageal squamous cell carcinoma (ESCC).

Journal of Clinical Oncology2024-01-2026 citations

Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors

Cancer Chemotherapy and Pharmacology2024-01-1110 citations

Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors

JAMA Oncology2023-09-2859 citations

Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed: The Study Protocol for the Randomized Controlled NEEDS Trial

Frontiers in Oncology2022-07-1329 citations

SKYSCRAPER-07: A phase III, randomized, double-blind, placebo-controlled study of atezolizumab with or without tiragolumab in patients with unresectable ESCC who have not progressed following definitive concurrent chemoradiotherapy.

Journal of Clinical Oncology2022-01-1932 citations